Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: -16.49%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While there was significant progress in the FDA review and commercial readiness for Anaphylm, the company faced substantial revenue declines and increased losses. The anticipation of Anaphylm's market entry and strategic preparations provide optimism, but financial challenges persist.Company Guidance
During the Aquestive Therapeutics First Quarter 2025 Earnings Conference Call, the company provided several key metrics and guidance for the upcoming periods. Dan Barber, CEO, highlighted that they are in the commercial prelaunch phase for Anaphylm, with an FDA action date anticipated in late January or early February of 2026. The company has prepared for the launch by attending 25 conferences and publishing 16 posters and manuscripts, expecting nearly 30 by the FDA action date. In regards to financials, total revenues decreased by 28% to $8.7 million compared to the first quarter of 2024, primarily due to a decrease in manufacturer and supply revenue. The net loss for the quarter was $22.9 million, and the company revised its full-year 2025 revenue guidance to $44 million to $50 million, with a non-GAAP adjusted EBITDA loss of $47 million to $51 million. The company plans to de-emphasize AQST-108 studies to free up capital for Anaphylm's launch, aiming for a fast start in 2026 if the FDA approves the product.Anaphylm FDA Review Progress
Aquestive is over a month into FDA review for Anaphylm Epinephrine Sublingual film. An FDA action date is anticipated for late January or early February of 2026.
Commercial Prelaunch Phase for Anaphylm
Aquestive has officially entered the commercial prelaunch phase for Anaphylm, focusing on assembling a marketing team with significant experience, including members who built EpiPen to a billion-dollar brand.
Increased Awareness Efforts
The company has attended 25 conferences and published 16 posters and manuscripts, with plans to reach 30 publications by the FDA action date.
Strategic Payer Engagement
Aquestive is leveraging existing distribution and payer contracts to prepare for Anaphylm's launch, aiming to save months of startup time.
---
AQST Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AQST Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $2.85 | $2.29 | -19.65% |
Mar 05, 2025 | $2.79 | $2.58 | -7.53% |
Nov 04, 2024 | $5.15 | $4.76 | -7.57% |
Aug 06, 2024 | $3.40 | $3.43 | +0.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aquestive Therapeutics (AQST) report earnings?
Aquestive Therapeutics (AQST) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Aquestive Therapeutics (AQST) earnings time?
Aquestive Therapeutics (AQST) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AQST EPS forecast?
AQST EPS forecast for the fiscal quarter 2025 (Q2) is -0.17.
---